BioCentury | Feb 25, 2021
Product Development

Cellarity turning network maps into programs for complex diseases with $123M series B

...the corner from a scientific discovery shop to an integrated drug discovery company.Founded in 2017, Cellarity Inc....
...be scaled, so we will be looking at different types of financing rounds,” said Chouraqui. Karen Tkach Tuzman Cellarity Inc. Flagship...
BioCentury | Jul 16, 2020
Management Tracks

Flagship picks Pfefer to lead Kintai, succeeding Tak

...of Novartis AG (NYSE:NVS; SIX:NOVN) and Bristol Myers Squibb Co. (NYSE:BMY), who became CEO of Cellarity Inc....
BioCentury | May 28, 2020
Management Tracks

In new role as Flagship ‘CEO partner,’ Chouraqui to become Cellarity’s chief exec

...Chouraqui will join Flagship Pioneering as he also becomes CEO of network-based drug discovery company Cellarity Inc....
...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) executive Paul-Peter Tak and ex-Novartis executive David Epstein. Paul Bonanos, Associate Editor Flagship Pioneering Cellarity Inc. Fabrice...
BioCentury | Dec 11, 2019
Emerging Company Profile

Flagship’s Cellarity maps out network-based drug discovery

...for a change in the network, that will be a much more efficient and potent.” Cellarity Inc....
...for its series B round, but declined to disclose a timeline for fund-raising. COMPANY PROFILE Cellarity Inc....
Items per page:
1 - 4 of 4
BioCentury | Feb 25, 2021
Product Development

Cellarity turning network maps into programs for complex diseases with $123M series B

...the corner from a scientific discovery shop to an integrated drug discovery company.Founded in 2017, Cellarity Inc....
...be scaled, so we will be looking at different types of financing rounds,” said Chouraqui. Karen Tkach Tuzman Cellarity Inc. Flagship...
BioCentury | Jul 16, 2020
Management Tracks

Flagship picks Pfefer to lead Kintai, succeeding Tak

...of Novartis AG (NYSE:NVS; SIX:NOVN) and Bristol Myers Squibb Co. (NYSE:BMY), who became CEO of Cellarity Inc....
BioCentury | May 28, 2020
Management Tracks

In new role as Flagship ‘CEO partner,’ Chouraqui to become Cellarity’s chief exec

...Chouraqui will join Flagship Pioneering as he also becomes CEO of network-based drug discovery company Cellarity Inc....
...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) executive Paul-Peter Tak and ex-Novartis executive David Epstein. Paul Bonanos, Associate Editor Flagship Pioneering Cellarity Inc. Fabrice...
BioCentury | Dec 11, 2019
Emerging Company Profile

Flagship’s Cellarity maps out network-based drug discovery

...for a change in the network, that will be a much more efficient and potent.” Cellarity Inc....
...for its series B round, but declined to disclose a timeline for fund-raising. COMPANY PROFILE Cellarity Inc....
Items per page:
1 - 4 of 4